Skip to main content
. 2021 Mar 9;14(5):613–623. doi: 10.1007/s40271-021-00501-7

Table 2.

Most commonly discussed symptoms in the overall population and by disease stage

Symptom Total (N = 30) NDMM (n = 18) RRMM (n = 12)
Bone pain 27 (90.0) 17 (94.0) 10 (83.0)
Fatigue/tiredness 26 (87.0) 16 (89.0) 10 (83.0)
Tingling hands or feet or restless leg 9 (30.0) 5 (28.0) 4 (33.0)
Infection 8 (27.0) 4 (22.0) 4 (33.0)
Sleepiness 4 (13.0) 2 (11.0) 2 (17.0)
Constipation 4 (13.0) 3 (17.0) 1 (8.0)
Muscle cramps 3 (10.0) 2 (11.0) 1 (8.0)
Headache 3 (10.0) 0 3 (25.0)
Insomnia 3 (10.0) 3 (17.0) 0

Data are presented as n (%). Symptoms discussed in more than one interview; includes both spontaneous and prompted mentions; one or more “other” symptoms (including anemia, bleeding, circulatory issues, cognitive issues, depression, diarrhea, dizziness, fainting, hair loss, heartburn, joint pain, lack of motivation, nausea, night sweats, nosebleeds, one-sided weakness, osteoporosis, other bone [e.g., dissolution, fracture], popliteal cyst, shortness of breath, sweating, tinnitus, weakness, uncertainty on feet, vision problems, vomiting, and weight loss) were mentioned in 15 (50.0%) interviews

NDMM newly diagnosed multiple myeloma, RRMM relapsed/refractory multiple myeloma